Matches in SemOpenAlex for { <https://semopenalex.org/work/W1675757788> ?p ?o ?g. }
- W1675757788 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PABackground: Blockade of the immune checkpoints PD-1 and CTLA-4 each results in improved overall survival in patients (pts) with metastatic melanoma using monotherapy. In a phase 1 dose-escalation study, dual inhibition of these pathways by nivolumab (NIVO) and ipilimumab (IPI) demonstrated encouraging antitumor activity.Methods: Treatment-naive pts with advanced melanoma were randomized (double-blind) 2:1 to IPI 3 mg/kg combined with either NIVO 1 mg/kg (NIVO+IPI combination group) or placebo (PBO; IPI alone group) every 3 weeks (Q3W) for 4 doses, followed by NIVO 3 mg/kg or PBO, respectively, Q2W until disease progression or unacceptable toxicity. Primary endpoint was investigator-assessed objective response rate (ORR) in BRAF wild-type (WT) pts. Secondary endpoints included progression-free survival (PFS), ORR in BRAF V600 mutation-positive (MT) pts, and safety.Results: In BRAF WT pts, ORR was 60% (43/72) in the NIVO+IPI group vs 11% (4/37) in the IPI group (P<0.0001); complete response reported in 12 (17%) and 0 pts, respectively. Median change in target lesions was 57% reduction for NIVO+IPI vs 4% increase for IPI alone. Median duration of response was not reached in either group. In BRAF WT pts, median PFS was 8.9 months for NIVO+IPI; 4.7 months for IPI (HR 0.40, 95% CI 0.22-0.71; P = 0.0012). Similar results for ORR and PFS favoring the combination were observed in BRAF MT pts (Table). A higher rate of drug-related grade 3-4 adverse events was observed in the NIVO+IPI group compared to IPI (Table), leading to more frequent discontinuation. Pts who discontinued NIVO+IPI due to study drug toxicity had a 67% response rate; most continue to respond. Immune-mediated AEs were manageable by standard treatment interventions, and the majority resolved with immune-modulating medication.Conclusion: NIVO+IPI significantly improved ORR and PFS compared to IPI alone in treatment-naive pts with advanced melanoma, and had a manageable safety profile.| Efficacy (evaluated in all randomized patients)BRAF WT ||:------------------------------------------------------ | --------------------------- || | BRAF WT | BRAF MT || | NIVO+IPI | IPI | NIVO+IPI | IPI || Randomized patients, N | 72 | 37 | 23 | 10 || ORR,% (95% CI) | 59.7 (47.5-71.1)a | 10.8 (3.0-25.4)a | 43.5 (23.2-65.5) | 0 (0-30.8) || Best overall response, n (%) || Complete response | 12 (16.7) | | 4 (17.4) | || Partial response | 31 (43.1) | 4 (10.8) | 6 (26.1) | || Stable disease | 10 (13.9) | 12 (32.4) | 5 (21.7) | 2 (20.0) || Progressive disease | 10 (13.9) | 16 (43.2) | 5 (21.7) | 7 (70.0) || Median PFS, mo (95% CI) | 8.9 (7.0, NE) | 4.7 (2.8, 5.3) | 7.4 (2.8, NE) | 2.7 (0.99, 5.4) || HR, (95% CI) | 0.40 (0.22-0.71) P = 0.0012 | 0.33 (0.1, 0.9)b || Safety (evaluated in all treated patients) || Patients reporting AE, n (%) | NIVO+IPI (N = 94) | IPI (N = 46) || | Any Grade | Grade 3-4 | Any Grade | Grade 3-4 || Treatment-related AEs | 86 (91.5) | 48 (51.1) | 42 (91.3) | 9 (19.6) |aP<0.0001; estimated odds ratio for objective response 12.23 (95% CI, 3.69-51.40)bDue to the small sample size in the BRAF MT subgroup, no P-value is provided NE = not estimableCitation Format: F. Stephen Hodi, Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald Linette, Nicolas Meyer, Jeffrey Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April Salama, Matthew H. Taylor, Linda Rollin, Christine Horak, Paul Gagnier, Jedd D. Wolchok. Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2860. doi:10.1158/1538-7445.AM2015-2860" @default.
- W1675757788 created "2016-06-24" @default.
- W1675757788 creator A5002027885 @default.
- W1675757788 creator A5003084219 @default.
- W1675757788 creator A5007052233 @default.
- W1675757788 creator A5011325668 @default.
- W1675757788 creator A5033482846 @default.
- W1675757788 creator A5033513252 @default.
- W1675757788 creator A5054656505 @default.
- W1675757788 creator A5056132643 @default.
- W1675757788 creator A5056507476 @default.
- W1675757788 creator A5061683749 @default.
- W1675757788 creator A5067794998 @default.
- W1675757788 creator A5069256182 @default.
- W1675757788 creator A5073549408 @default.
- W1675757788 creator A5075485963 @default.
- W1675757788 creator A5076793020 @default.
- W1675757788 creator A5078083181 @default.
- W1675757788 creator A5084480627 @default.
- W1675757788 creator A5084967339 @default.
- W1675757788 creator A5086165685 @default.
- W1675757788 creator A5089516753 @default.
- W1675757788 date "2015-08-01" @default.
- W1675757788 modified "2023-09-26" @default.
- W1675757788 title "Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone" @default.
- W1675757788 doi "https://doi.org/10.1158/1538-7445.am2015-2860" @default.
- W1675757788 hasPublicationYear "2015" @default.
- W1675757788 type Work @default.
- W1675757788 sameAs 1675757788 @default.
- W1675757788 citedByCount "1" @default.
- W1675757788 countsByYear W16757577882015 @default.
- W1675757788 crossrefType "proceedings-article" @default.
- W1675757788 hasAuthorship W1675757788A5002027885 @default.
- W1675757788 hasAuthorship W1675757788A5003084219 @default.
- W1675757788 hasAuthorship W1675757788A5007052233 @default.
- W1675757788 hasAuthorship W1675757788A5011325668 @default.
- W1675757788 hasAuthorship W1675757788A5033482846 @default.
- W1675757788 hasAuthorship W1675757788A5033513252 @default.
- W1675757788 hasAuthorship W1675757788A5054656505 @default.
- W1675757788 hasAuthorship W1675757788A5056132643 @default.
- W1675757788 hasAuthorship W1675757788A5056507476 @default.
- W1675757788 hasAuthorship W1675757788A5061683749 @default.
- W1675757788 hasAuthorship W1675757788A5067794998 @default.
- W1675757788 hasAuthorship W1675757788A5069256182 @default.
- W1675757788 hasAuthorship W1675757788A5073549408 @default.
- W1675757788 hasAuthorship W1675757788A5075485963 @default.
- W1675757788 hasAuthorship W1675757788A5076793020 @default.
- W1675757788 hasAuthorship W1675757788A5078083181 @default.
- W1675757788 hasAuthorship W1675757788A5084480627 @default.
- W1675757788 hasAuthorship W1675757788A5084967339 @default.
- W1675757788 hasAuthorship W1675757788A5086165685 @default.
- W1675757788 hasAuthorship W1675757788A5089516753 @default.
- W1675757788 hasConcept C121608353 @default.
- W1675757788 hasConcept C126322002 @default.
- W1675757788 hasConcept C143998085 @default.
- W1675757788 hasConcept C2777658100 @default.
- W1675757788 hasConcept C2777701055 @default.
- W1675757788 hasConcept C2780030458 @default.
- W1675757788 hasConcept C2781433595 @default.
- W1675757788 hasConcept C2994587330 @default.
- W1675757788 hasConcept C502942594 @default.
- W1675757788 hasConcept C59491497 @default.
- W1675757788 hasConcept C71924100 @default.
- W1675757788 hasConceptScore W1675757788C121608353 @default.
- W1675757788 hasConceptScore W1675757788C126322002 @default.
- W1675757788 hasConceptScore W1675757788C143998085 @default.
- W1675757788 hasConceptScore W1675757788C2777658100 @default.
- W1675757788 hasConceptScore W1675757788C2777701055 @default.
- W1675757788 hasConceptScore W1675757788C2780030458 @default.
- W1675757788 hasConceptScore W1675757788C2781433595 @default.
- W1675757788 hasConceptScore W1675757788C2994587330 @default.
- W1675757788 hasConceptScore W1675757788C502942594 @default.
- W1675757788 hasConceptScore W1675757788C59491497 @default.
- W1675757788 hasConceptScore W1675757788C71924100 @default.
- W1675757788 hasLocation W16757577881 @default.
- W1675757788 hasOpenAccess W1675757788 @default.
- W1675757788 hasPrimaryLocation W16757577881 @default.
- W1675757788 hasRelatedWork W1478180867 @default.
- W1675757788 hasRelatedWork W2187167680 @default.
- W1675757788 hasRelatedWork W2490123200 @default.
- W1675757788 hasRelatedWork W2586438189 @default.
- W1675757788 hasRelatedWork W2604291631 @default.
- W1675757788 hasRelatedWork W2739577140 @default.
- W1675757788 hasRelatedWork W2748949248 @default.
- W1675757788 hasRelatedWork W2803886910 @default.
- W1675757788 hasRelatedWork W2891694121 @default.
- W1675757788 hasRelatedWork W2891790933 @default.
- W1675757788 hasRelatedWork W2900900207 @default.
- W1675757788 hasRelatedWork W2955895289 @default.
- W1675757788 hasRelatedWork W2995137405 @default.
- W1675757788 hasRelatedWork W3000502941 @default.
- W1675757788 hasRelatedWork W3004291089 @default.
- W1675757788 hasRelatedWork W3042095160 @default.
- W1675757788 hasRelatedWork W3097406293 @default.
- W1675757788 hasRelatedWork W3098111277 @default.
- W1675757788 hasRelatedWork W2189072762 @default.
- W1675757788 hasRelatedWork W2480214640 @default.
- W1675757788 isParatext "false" @default.
- W1675757788 isRetracted "false" @default.
- W1675757788 magId "1675757788" @default.